他雷替尼治疗ROS1阳性非小细胞肺癌:TRUST研究
TRUST-I与TRUST-II为II期单臂多中心试验,汇总分析他雷替尼治疗ROS1阳性非小细胞肺癌的疗效与安全性。TKI初治患者确认客观缓解率88.8%、颅内客观缓解率76.5%,TKI经治患者分别为55.8%和65.6%。他雷替尼显示出高缓解率、持久缓解、稳健颅内活性、延长无进展生存期及良好安全性,神经系统不良事件发生率低。
要点
- TKI初治患者确认客观缓解率88.8%,颅内客观缓解率76.5%。
- TKI经治患者确认客观缓解率55.8%,颅内客观缓解率65.6%。
- 每日口服600 mg安全性可管理,因不良事件导致停药率6.5%。
核心结论
- 他雷替尼在TKI初治和经治ROS1阳性非小细胞肺癌患者中显示出高缓解率、持久缓解、稳健颅内活性、延长无进展生存期、良好安全性及低神经系统不良事件发生率。
研究设计与样本
- TRUST-I和TRUST-II为II期、单臂、开放标签、非随机、多中心试验。
- 疗效结局汇总自TRUST-I和TRUST-II关键队列,截至2024年6月7日可评估疗效人群共273例。
- 安全性人群为所有接受每日一次口服他雷替尼600 mg治疗的患者,汇总自他雷替尼临床研究项目,共352例。
- 主要终点为独立评审委员会评估的确认客观缓解率。
主要发现
- TKI初治患者(n=160)确认客观缓解率为88.8%,颅内客观缓解率为76.5%。
- TKI经治患者(n=113)确认客观缓解率为55.8%,颅内客观缓解率为65.6%。
- TKI初治患者中位缓解持续时间为44.2个月,中位无进展生存期为45.6个月。
- TKI经治患者中位缓解持续时间为16.6个月,中位无进展生存期为9.7个月。
- G2032R突变患者确认客观缓解率为61.5%(13例中8例)。
关键数值与推荐
- 接受他雷替尼600 mg每日一次治疗的352例患者中,最常见治疗中出现的不良事件为胃肠道事件(88%)、天冬氨酸氨基转移酶升高(72%)和丙氨酸氨基转移酶升高(68%),大多数为1级。
- 神经系统治疗中出现的不良事件不常见(头晕21%;味觉障碍15%),大多为1级。
- 导致停药的治疗中出现的不良事件发生率为6.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1+ non-small cell lung cancer. METHODS: TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials. Efficacy outcomes were pooled from TRUST-I and TRUST-II pivotal cohorts. The safety population comprised all patients treated with once-daily oral taletrectinib 600 mg pooled across the taletrectinib clinical program. The primary end point was independent review committee-assessed confirmed objective response rate (cORR). Secondary outcomes included intracranial (IC)-ORR, progression-free survival (PFS), duration of response (DOR), and safety. RESULTS: As of June 7, 2024, the efficacy-evaluable population included 273 patients in TRUST-I and TRUST-II. Among TKI-naïve patients (n = 160), the cORR was 88.8% and the IC-cORR was 76.5%; in TKI-pretreated patients (n = 113), the cORR was 55.8% and the IC-cORR was 65.6%. In TKI-naïve patients, the median DOR and median PFS were 44.2 and 45.6 months, respectively. In TKI-pretreated patients, the median DOR and median PFS were 16.6 and 9.7 months. The cORR in patients with G2032R mutation was 61.5% (8 of 13). Among 352 patients treated with taletrectinib 600 mg once daily, the most frequent treatment-emergent adverse events (TEAEs) were GI events (88%) and elevated AST (72%) and ALT (68%); most were grade 1. Neurologic TEAEs were infrequent (dizziness, 21%; dysgeusia, 15%) and mostly grade 1. TEAEs leading to discontinuations (6.5%) were low. CONCLUSION: Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients.
引用
- Pérol M, Li W, Pennell NA, et al. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025. PMID: 40179330. doi:10.1200/JCO-25-00275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。